Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis

International Urology and Nephrology

Volumn 47, Issue 3, 2015, Pages 527-535

  Zhai, Chun Juan ^a   Yang, Xiao Wei ^a   Sun, Jing ^a   Wang, Rong ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Calcium; Lanthanum carbonate; Meta analysis; Systematic review

Indexed keywords

CALCIUM; CALCIUM BASED PHOSPHATE BINDER; CALCIUM SALT; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; UNCLASSIFIED DRUG; CALCIUM CARBONATE; CHELATING AGENT; LANTHANUM; PHOSPHORUS;

ARTICLE; BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CALCIUM BONE LEVEL; CHRONIC KIDNEY DISEASE; COCHRANE LIBRARY; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; HYPERCALCEMIA; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS; NAUSEA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; VOMITING; BLOOD; BONE DENSITY; COMPARATIVE STUDY; DRUG EFFECTS; RADIOGRAPHY; RENAL INSUFFICIENCY, CHRONIC; VASCULAR CALCIFICATION;

BONE DENSITY; CALCIUM; CALCIUM CARBONATE; CHELATING AGENTS; HUMANS; HYPERCALCEMIA; LANTHANUM; PARATHYROID HORMONE; PHOSPHORUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; VASCULAR CALCIFICATION;

EID: 84925500186     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-014-0876-x     Document Type: Article

References (29)

1. Levey AS, Coresh J (2012) Chronic kidney disease. Lancet 379(9811):165–180. doi:10.1016/S0140-6736(11)60178-5
2. Bhan I, Thadhani R (2009) Vascular calcification and ESRD: a hard target. Clin J Am Soc Nephrol 4(Suppl 1):S102–S105. doi:10.2215/CJN.04800709
3. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global O (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69(11):1945–1953. doi:10.1038/sj.ki.5000414
4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol: JASN 15(8):2208–2218. doi:10.1097/01.ASN.0000133041.27682.A2
5. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK (2008) Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52(3):519–530. doi:10.1053/j.ajkd.2008.03.020
6. Ohya M, Otani H, Kimura K, Saika Y, Fujii R, Yukawa S, Shigematsu T (2011) Vascular calcification estimated by aortic calcification area index is a significant predictive parameter of cardiovascular mortality in hemodialysis patients. Clin Exp Nephrol 15(6):877–883. doi:10.1007/s10157-011-0517-y
7. Damment SJ, Pennick M (2008) Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. Clin Pharmacokinet 47(9):553–563
8. Hutchison AJ, Barnett ME, Krause R, Kwan JT, Siami GA, Group SPDLS (2008) Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract 110(1):c15–c23. doi:10.1159/000149239
9. Shigematsu T, Lanthanum Carbonate Research G (2008) Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Ther Apher Dial 12(1):55–61. doi:10.1111/j.1744-9987.2007.00541.x
10. Freemont AJ, Hoyland JA, Denton J, SPDSG Lanthanum Carbonate (2005) The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol 64(6):428–437
11. Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskuhler A (2005) Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 100(1):c8–c19
12. Lee YK, Choi HY, Shin SK, Lee HY (2013) Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study. Clin Nephrol 79(2):136–142. doi:10.5414/cn107362
13. Ohtake T, Kobayashi S, Oka M, Furuya R, Iwagami M, Tsutsumi D, Mochida Y, Maesato K, Ishioka K, Moriya H, Hidaka S (2013) Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study. J Cardiovasc Pharmacol Ther 18(5):439–446
14. Scaria PT, Gangadhar R, Pisharody R (2009) Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease. Indian J Pharmacol 41(4):187–191. doi:10.4103/0253-7613.56074
15. Shigematsu T, Sakai T, Kono T, Kimura Y, Takuma Y, Tsuruta Y, Mori Y, Taki M, Moriishi M, Minakuchi J, Obayashi S, Miyake S, Emoto H, Furuhashi M, Tsujimoto Y, Arisaka H, Ishizaki M, Shimoyama H, Kim S, Hirose S, Kurosawa A, Matsui N, Nakazawa R, Watanabe T, Kabaya T, Tanaka Y, Takahashi T, Ozawa T, Nakamura K, Nishioka M, Higashi H, Koga N (2008) Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis, patients with hyperphosphatemia. Clin Nephrol 70(5):404–410
16. Soriano S, Ojeda R, Rodriguez M, Almaden Y, Rodriguez M, Martin-Malo A, Aljama P (2013) The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients. Clin Nephrol 80(1):17–22. doi:10.5414/cn107764
17. Spasovski GB, Sikole A, Gelev S, Masin-Spasovska J, Freemont T, Webster I, Gill M, Jones C, De Broe ME, D’Haese PC (2006) Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 21(8):2217–2224. doi:10.1093/ndt/gfl146
18. Toida T, Fukudome K, Fujimoto S, Yamada K, Sato Y, Chiyotanda S, Kitamura K (2012) Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study. Clin Nephrol 78(3):216–223
19. Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG (2011) Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology 16(3):290–298
20. Wada K, Wada Y (2014) Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial. Ther Apher Dial. doi:10.1111/1744-9987.12153
21. Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, Lok CE, Fitchett D, Tsuyuki RT (2013) Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 382(9900):1268–1277. doi:10.1016/S0140-6736(13)60897-1
22. Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GFM (2009) Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 54(4):619–637
23. Zhang C, Wen J, Li Z, Fan J (2013) Efficacy and safety of lanthanum carbonate on chronic kidney disease–mineral and bone disorder in dialysis patients: a systematic review. BMC Nephrol 14(1):226. doi:10.1186/1471-2369-14-226
24. Guo H, Zhang X, Tang S, Zhang S (2013) Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis—system review of lanthanum carbonate. Ren Fail 35(10):1455–1464. doi:10.3109/0886022X.2013.828365
25. National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(4 Suppl 3):S1–S201
26. Brennan A, Akehurst R, Davis S, Sakai H, Abbott V (2007) The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease. Value Health 10(1):32–41. doi:10.1111/j.1524-4733.2006.00142.x
27. Goto S, Komaba H, Moriwaki K, Fujimori A, Shibuya K, Nishioka M, Kim JI, Yoshiya K, Shin J, Hasegawa H, Taniguchi M, Fujii H, Nishi S, Kamae I, Fukagawa M (2011) Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. Clin J Am Soc Nephrol 6(6):1375–1384. doi:10.2215/CJN.08841010
28. Park H, Rascati KL, Keith MS, Hodgkins P, Smyth M, Goldsmith D, Akehurst R (2011) Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective. Value Health 14(8):1002–1009. doi:10.1016/j.jval.2011.05.043
29. Vegter S, Tolley K, Keith MS, Postma MJ (2011) Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis. Value Health 14(6):852–858. doi:10.1016/j.jval.2011.05.005